Archive

ASH 2015: Clinical discussant in this ASH/FDA session, Professor Paul Richardson (Harvard medical School, Boston, USA), discusses the clinical relevance of the new oral proteazome inhibitor ixazomib and two new monoclonal antibodies daratumumab and elotuzumab approved in the last few weeks by the FDA

Experts try to provide clarity in dizzying myeloma landscape by Thomas R. Collins: There’s no doubt that the bonanza of new multiple myeloma therapies is a blessing to… read more.

ASH 2015: Interview with Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA, USA) gives a flavour of the excitement generated at ASH

ASH 2015 proved to be all that we’d hoped for! We’ve witnessed unprecedented change in multiple myeloma with CR and VGPR percentages higher than ever… and most of this… read more.

ASH 2015: New therapies explored in peripheral T-cell lymphoma

by Thomas R. Collins: In early results, patients newly diagnosed with peripheral T-cell lymphoma (PTCL) treated with the HDAC-inhibitor belinostat, and CHOP therapy, tolerated the combination well at… read more.

ASH 2015: Early findings on oral therapies for relapsed/refractory DLBCL unveiled

by Thomas R. Collins: Early results show that venetoclax, a BCL-2-inhibitor, produced relatively good response rates in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.1

ASH 2015: Risk profile key in transplant decisions in non-Hodgkin lymphoma

by Thomas R. Collins: There could be a role for consolidation autologous stem cell transplantation for patients with diffuse, aggressive non-Hodgkin lymphomas (NHL) who are at high risk… read more.

ASH 2015: Investigators update results on key carfilzomib studies: ENDEAVOR and ASPIRE

by Thomas R. Collins: A subgroup analysis of data from the ENDEAVOR trial, comparing carfilzomib and dexamethasone (Kd) to bortezomib and dexamethasone (Vd) — shows improved progression-free survival (PFS)… read more.

ASH 2015: Ixazomib shows promise in variety of settings, according to early trial results

by Thomas R. Collins: Fresh off its approval in the U.S. in the relapsed/refractory setting of multiple myeloma, ixazomib continues to be examined in other patient pools, with… read more.

ASH 2015: Trials exploring new settings for monoclonal antibodies in MM

by Thomas R. Collins: Trials are continuing to explore potential new settings for daratumumab and elotuzumab, two monoclonal antibodies that were recently approved for use in multiple myeloma… read more.

Viagra ups insulin sensitivity in prediabetes

by Bruce Sylvester: Treatment with sildenafil, marketed as Viagra and other trade names, appears to improve insulin sensitivity in persons with prediabetes, as well as lowering a biological… read more.

ASH 2015: Capitalising on recent advances in HL – R/R HL in the brentuximab vedotin era. Professor Ajay Gopal, Seattle Cancer Care Alliance, WA, USA. Dr Robert Chen, City of Hope, Duarte, CA, USA and Professor John Sweetenham, Huntsman Cancer Institute, Saltlake City, USA., discuss where they see the optimal setting for use of brentuximab vedotin following updates at ASH 2015. Click on the video image to view.

ASH 2015: Checkpoint blockade vision of the future. Professor Stephen Ansell, Mayo Clinic, Rochester, MN, USA discusses the extended follow-up phase 1 nivolumab study in R/R classic HL. Click video image to view.

by Thomas R. Collins: Studies on PD-1 blockade in classical Hodgkin lymphoma are still only entering Phase 2, but the early results and a history of success in… read more.

ASH 2015: Brentuximab vedotin data shows durable CR five years on – is this cure? Dr Robert Chen, (City of Hope, Duarte, CA, USA) discusses the five year survival data presented at ASH; who of the CR patients to watch and wait and who to go onto allo-SCT; and whether these patients are now cured. Click video image to view.

by Thomas R. Collins: Five years after the last patient’s last treatment visit, the final results are in for brentuximab vedotin’s (BV) pivotal Phase 2 study, offering perhaps… read more.